Full-Time
Global Program Clinical Head
Neuroscience
Posted on 6/20/2026
Novartis
10,001+ employees
Global pharmaceutical company delivering science-based innovations
No salary listed
London, UK + 2 more
More locations: Dublin, Ireland | Sant Cugat del Vallès, Barcelona, Spain
Hybrid
Relocation not offered; role based in London, Barcelona, or Dublin.
 Biology & Biotech (1) |
|---|
- MD or equivalent (preferred), PhD, or PharmD degree required. Experience and background in Neuroscience, Gene Therapy, Neuromuscular, Neurodegeneration and/or Movement disorders is essential for this position.
- Extensive expertise in clinical trial design, regulatory expectations, and global development strategy
- Proven ability to lead cross-functional teams and influence senior stakeholders in complex matrix settings
- Deep understanding of benefit-risk assessment and patient safety considerations in clinical development
- Demonstrated experience engaging external stakeholders, including regulatory authorities and scientific experts
- Strong strategic thinking, communication, and decision-making skills to drive clarity and momentum globally
- Lead global clinical programs across indications, ensuring delivery aligned with regulatory and market access needs
- Drive clinical strategy and execution through an endorsed clinical development plan aligned to target product profile
- Lead and inspire global clinical teams, building collaboration, pace, and accountability across a matrix environment
- Own program-level benefit-risk assessment, maintaining strong patient focus and scientific integrity throughout development
- Oversee design and delivery of clinical trials, ensuring quality, compliance, and timely execution against milestones
- Lead development of key clinical and regulatory documents, ensuring clarity, consistency, and strategic alignment
- Represent Clinical Development in governance and external engagements, including interactions with regulators and experts
- Budget Management
- Clinical Trials
- Coaching
- Compliance
- Cross-Functional Teams
- Leadership
- People Management
- Risk Management
- Risk Monitoring
- Strategy
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Your Connections
People at Novartis who can refer or advise you
Simplify's Take
What believers are saying
- Precision oncology market growth validates Novartis's biomarker-driven cancer treatment focus.
- Pluvicto launch in India expands access to targeted metastatic prostate cancer therapy.
- Global health R&D investment of $500 million strengthens malaria and neglected disease programs.
What critics are saying
- Pluvicto faces regulatory delay or narrow label risk affecting franchise growth within 6–12 months.
- RTL access bottleneck exists due to limited nuclear medicine network in key regions like Italy.
- Molecular glue R&D bet risks capital burn if induced-proximity programs fail target validation.
What makes Novartis unique
- Novartis pioneers radioligand therapy for precision cancer care targeting tumors globally.
- The company integrates AI and real-world evidence to advance prostate cancer treatment insights.
- Novartis leads in molecular glue R&D partnerships, targeting unapproachable drug mechanisms.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%Radioligandi, the evolution of the system changes from new organizational models. MILAN (ITALPRESS) - Therapies with radioligands represent a new chapter in the fight against cancer, through the pioneering approach of therapy, in which diagnosis and therapy are integrated; radioligands are able to vehicular radiation directly to cells that express the specific target, with targeted action and represent an area of research in evolution in the treatment of advanced tumors; parallel there emerges the need for new organized models. "The therapy with radioligands is a significant innovation, because it allows to selectively affect the disease based on the biological characteristics of the tumor - explains Fabio Calabrò, Director UOC Medical Oncology 1, Istituto Nazionale Tumori "Regina Elena" in Rome -. It is an approach that integrates diagnosis and treatment and allows to treat patients who can really benefit from it, opening new opportunities in personalized medicine." Novartis is among the pioneering companies in the development of therapies with radioligands, today considered among the most advanced platforms of precision medicine in oncology. In this context, Italy is a strategic node for the global production of radioligands, thanks to the presence of highly specialized sites, such as Ivrea and Saluggia, able to guarantee the availability of these therapies for patients internationally. In addition to therapeutic innovation, a decisive challenge emerges today: the ability of the system to translate innovation into real access. The growing demand, combined with a still uneven distribution of infrastructure, is likely to generate inequalities among patients. Without a system fully ready to accept this innovation, even the most advanced advances risk not to be translated into concrete and fair benefits for all. The diffusion of the RLT requires an evolution of organizational models: more integration between oncology and nuclear medicine, more efficient processes and, above all, an increase in the operational capacity of the centers to ensure a timely grip and a continuity of assistance. The monitoring of the centres shows a progressive strengthening of the system's capacity to welcome innovation in the national territory, with a total of 47 active centres distributed in 18 Italian regions, but at the same time shows an uneven distribution, with a greater concentration in the regions of the North and Center. In particular, Lombardy is confirmed as one of the areas with greater density of centers, followed by Lazio, Campania and Emilia-Romagna, while some regions of the South and the Islands, such as Calabria and Sardinia, are represented by a more limited number of structures. This trend reflects an evolving system in its organizational and welfare capacity, but still characterized by territorial differences. Overall, the data shows a dual trend: on the one hand, the consolidation of the national network and the expansion of the offer, on the other, the need to continue in the strengthening of organizational models and regional networks to ensure increasingly fair and homogeneous access to care throughout the territory. "The spread of radioligand therapy poses significant organizational challenges, both in terms of the ability of centers and access for patients - says Claudio Rossetti, Director S.C. Nuclear Medicine Niguarda Hospital and Coordinator of the International Department of Nuclear Medicine of Lombardy -. The collaboration between centers is a key factor: shared models allow to manage in a coordinated way the different phases of the treatment, improving the accessibility and quality of the grip". In this direction there are concrete experiences such as the RE-MODEL project, developed by Novartis in collaboration with the Politecnico di Milano, which demonstratesano how it is possible to rethink the organization of care paths to optimize flows, increase the capacity of centers and make innovation really accessible throughout the territory. The project, realized with the involvement of more than 20 centres of Nuclear Medicine at the national level, has evidenced how evolved organizational models, which enable patient day management, can lead to an increase in operational capacity up to 80%, allowing to treat up to 15% more patients through more efficient use of available resources and a remodelling of the use of spaces and staff producing an increase of more than 40% of the bed rotation index. "Today the value of innovation is also measured in the ability of the system to make it concretely accessible. This is why the capacity of the healthcare system becomes central to accept and integrate this innovation: in addition to the availability of the therapeutic platform, they serve organization, multidisciplinary integration and adequate operational capacity of the centers. The challenge today is not only to innovate, but to make innovation really available for everyone", concludes Marco Amorese, Head of Innovation, Business Excellence & Execution and Mature Brands, Novartis. - Novartis press office photos - (ITALPRESS).
Rewrite this news in-house style based on British English without Plagiarism, remove direct speeches, and Use simple and uncomplicated language as far as possible. Thursday, June 11, 2026 Orionis Biosciences has entered into an expanded multi-year collaboration with Novartis to discover and develop molecular glue medicines targeting difficult-to-treat diseases across multiple therapeutic areas. The agreement builds on the existing relationship between the two companies and aims to advance the use of induced proximity approaches in drug discovery. Under the collaboration, Orionis and Novartis will use Orionis's Allo-Glue(TM) platform together with its artificial intelligence-driven discovery engine to accelerate target identification, ligase profiling and molecular glue optimisation. The combined technologies are designed to support the systematic discovery of small-molecule molecular glues, which work by bringing proteins into close proximity to modify biological processes and influence disease-related targets. As part of the agreement, Orionis will receive an upfront payment of USD 40 million. The company is also eligible to receive up to USD 1.4 billion in research, development and commercial milestone payments, in addition to tiered royalties on future product sales arising from the collaboration. The expanded partnership reflects continued confidence in Orionis's molecular glue platform and its progress in developing scalable and rational approaches for discovering this emerging class of medicines. Orionis noted that recent advances in artificial intelligence and robotic automation have improved several stages of molecular glue discovery, including identifying productive target-ligase pairs and optimising potential drug candidates. These developments have helped strengthen the platform's capabilities and support larger collaborative programmes. The companies will explore the potential of molecular glue technologies across a range of therapeutic areas, with the goal of expanding the number of biological targets that can be addressed through future treatments.
Strengthening health systems together: Novartis becomes an SCBF member. June 8, 2026 Reading time: SCBF is pleased to welcome Novartis as its new member. Novartis has built the industry's largest pipeline of treatments for malaria and neglected tropical diseases, backed by more than USD 500 million in investment in global health R&D since 2021, and recently announced a significant expansion of its community health programs around the world to close gaps in care for chronic diseases. As part of these efforts, Novartis plans to expand initiatives to speed up diagnosis and treatment for heart disease and cancer in at least 10 low- and middle-income countries by 2030. As a new member, Novartis will engage with SCBF's network to exchange insights and contribute its experience in developing and implementing health system strengthening efforts at scale. Cover Pic Courtesy: Novartis, Novartis Community Health Initiative launch event in Oaxaca, Mexico
On Clinical Trials Day, Howard University emphasizes trust and participation in research. May 20, 2026 2 minutes May 20 is Clinical Trials Day, and Howard University is marking the observance through ongoing efforts to improve trust and participation in clinical studies for communities traditionally overlooked in the research process. According to Celia J. Maxwell, professor of medicine and director of Howard University's Clinical Trials Unit, the university is currently involved in approximately 13 clinical trials, including studies in startup and contracting phases. Howard University's clinical trials program has also been strengthened through collaborations with industry partners such as Novartis and Sanofi, which help expand access to research and emerging treatments. "Clinical trials are highly regulated and include strict protections around participant privacy and study integrity," Maxwell says. "They are essential because they help determine whether treatments are safe and effective across diverse populations." At Howard University, ongoing clinical trial studies span a wide range of conditions, including asthma, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, eczema, hidradenitis suppurativa, chronic hives, heart disease, and chronic kidney disease. Maxwell said the goal is to expand access to emerging treatments while ensuring that communities most affected are represented in medical research. Historically, African Americans and other groups have been excluded from medical research, contributing to lingering mistrust shaped in part by the infamous Tuskegee Study. Maxwell said modern clinical trials now operate under strict safeguards, including informed consent, federal oversight, and ongoing safety monitoring. In recent years, Howard University and Howard University Hospital have also worked to strengthen their clinical research infrastructure. Investments have included expanded staffing, pharmacy capabilities, data systems, and community outreach efforts designed to support long-term growth in clinical research. Maxwell noted several ways for Howard students and community members to become involved in clinical research. Individuals can learn about ongoing studies and opportunities through resources such as ClinicalTrials.gov, Howard University's Office of Regulatory Research Compliance, university outreach events, community health programs and fairs, training and mentorship opportunities, and CITI research training programs. She added that students interested in research careers can seek opportunities through faculty mentorship, clinical research training programs, internships, and volunteer experiences connected to ongoing studies. Observed globally each May 20, Clinical Trials Day recognizes the anniversary of what is considered the first randomized clinical trial, conducted in 1747 by British naval surgeon James Lind to study treatments for scurvy among sailors. Today, the observance also provides an opportunity to educate the public about the importance of clinical trials in advancing medicine and improving patient care. Jul 28, 2021 4 minutes Jun 22, 2022 4 minutes Are you a member of the media? Its public relations team can connect you with faculty experts and answer questions about Howard University news and events.
How can Impactstewards improve heart failure care? Heart failure is a serious condition with a significant impact on the daily lives of patients and their loved ones. Fortunately, over the past decade, there have been many advancements in heart failure care. However, understandably, these improvements have not yet been fully implemented everywhere in the Netherlands. This prompted Impact Stewards and Novartis to join forces. Impactstewards gathered insights from cardiologists at six hospitals and compiled them into the Practice Paper: Heart Failure Care of the Future. Why improving heart failure care doesn't happen automatically. Developments in heart failure care have advanced rapidly over the past ten years. New scientific insights, guidelines, home monitoring tools, and communication channels have emerged. Yet, implementing these improvements in heart failure care does not always take off smoothly. As a result, a patient may have a higher chance of receiving guideline-based treatment in one hospital compared to another. In the daily hustle of clinical care, it can be challenging for heart failure teams to address this systematically. Six hospitals share how they improve heart failure care. As a pharmaceutical company, Novartis is in contact with almost all cardiologists in the Netherlands. It asked Impact Stewards for help: Could Impactstewards collaborate to gather insights from centres with outstanding examples of innovative heart failure care? This way, cardiologists can learn from each other more quickly. In the Practice Paper: Heart Failure Care of the Future, Impactstewards compile insights from six hospitals. Cardiologists from Catharina Hospital, Maastricht UMC+, Pantein Maasziekenhuis, Rijnstate, Spaarne Gasthuis, and St. Antonius share their experiences. How have they implemented new guidelines and improved the accessibility and quality of cardiological care? And how are they preparing for the heart failure team of tomorrow? What does the future of heart failure care look like? Six hospitals share how they have structured their heart failure care. What does the future of heart failure care look like? The paper includes recommendations to improve heart failure care: * Rapidly achieving Optimal Medical Therapy (OMT) in an outpatient setting * Home monitoring and restructuring patient support * Developing a standardised and multidisciplinary care pathway * Facilitating and encouraging self-management * Gaining insights through data analysis of the patient population * Optimal collaboration within the heart failure team The Practice Paper: Heart Failure Care of the Future is now available to healthcare providers via Novartis: "We created a Practice Paper with examples from six centres, showing how they improve heart failure care. By learning from others, you can implement these improvements faster." - Naomi Tielen, Impact Steward How Impact Stewards contributes. Impact Stewards helps organisations in healthcare and life sciences do better - for patients and the planet. Its mission is to improve the accessibility, affordability, and sustainability of its healthcare system. Its Impact Stewards are seasoned experts in healthcare and life sciences. Together, Impactstewards oversee the entire healthcare system: from medical innovation to patient care. Impactstewards leverage its sector knowledge, advisory skills, and transformation expertise to achieve sustainable change. In this project, Impact Stewards serves as an independent partner. Impactstewards represent the interests of all stakeholders and ensure the neutrality, transparency, and diligence of the process, decision-making, and outcomes as described in this Practice Paper.